Insights

More Articles Back to Article

DIA China 2021: China GVP: Lifecycle Pharmacovigilance and Patient Safety

In May 2021, the NMPA in China issued an announcement about Good Pharmacovigilance Practice, hereafter referred to as GVP, the first pharmacovigilance guideline issued in accordance with China’s new Drug Administration Law of the People’s Republic of China, the first time the term “pharmacovigilance” is officially reflected in the Drug Administration Law of China.